Biodesix Inc【BDSX】株式ニュース | ADVFN

US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

登録

Biodesix Inc (BDSX)

1.03

-0.01

(-0.96%)

終了 2月2日 6:00AM

1.02

-0.01

(-0.97%)

取引時間後: 9:59AM

個人投資家向けのプロ仕様のツール。

プレミアム

Form 8-K - Current report

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited)

LOUISVILLE, Colo., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic...

Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study

LOUISVILLE, Colo., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form EFFECT - Notice of Effectiveness

Form EFFECT - Notice of Effectiveness

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 4 - Statement of changes in beneficial ownership of securities

Form S-3 - Registration statement under Securities Act of 1933

georgie18

georgie18 4週前

BDSX...$1.55...🥳...https://www.globenewswire.com/news-release/2025/01/07/3005157/0/en/Biodesix-Announces-Publication-of-a-New-Nodify-CDT-Clinical-Validation-Study.html

PonkenPlonken

PonkenPlonken 2月前

Mr Schuler is buying shares again

tw0122

Is selling $250 million in stock fro time to time on the downside.. Separately, Biodesix filed a registration statement to sell up to $250 million in securities from time to time.

tw0122

Lung diagnostics cancer revenues improving still has $33m cash $1.49 +'14%

AJ Freely

AJ Freely 2年前

$BDSX - Up 12%/ Current Price $1.34.
Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2® Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules

1hot toddy

1hot toddy 2年前

WOOOOOOW 130K SHARES BUY NOW 2.6 MIL SHARE BUY $

3 MILLION $ BUY $$$$$$$$$$$$$$$$$$$$$$

Leg58

Lots if potential but will public offering dilute price?

Leg58

Lots if potential but will public offering dilute price?

subslover

subslover 2年前

Earnings look good.

subslover

subslover 2年前

Earnings look good.

MiamiGent

MiamiGent 2年前

BDSX Has news this morning!

The contract covers the company’s entire lung diagnostic portfolio: Nodify XL2®, Nodify CDT®, VeriStrat®, GeneStrat® ddPCR, and GeneStrat NGS™ testing.

https://investors.biodesix.com/news-releases/news-release-details/biodesix-awarded-us-federal-supply-schedule-contract-its

https://stockcharts.com/h-sc/ui?s=BDSX

carusso

carusso 2年前

crudeoil24

crudeoil24 2年前

LET'S GO BDSX !!!!!

crudeoil24

crudeoil24 2年前

Biodesix to Participate in Two Upcoming Investor Conferences in September
6:00 am ET September 6, 2022 (BusinessWire) Print
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will participate in two upcoming investor conferences:

Morgan Stanley 20th Annual Global Healthcare Conference Date: Tuesday, September 13, 2022 at 9:10 a.m. ET Format: Fireside Chat and 1x1 meetings Location: Sheraton Hotel, New York, NY Details: The fireside chat will be webcast live and available for replay under "News & Events" in the Investors section of the Company's website at www.biodesix.com.

H.C. Wainwright 24th Annual Global Investment Conference Dates: September 12-14, 2022 Format: 1x1 meetings Location: Lotte New York Palace Hotel, New York, NY

crudeoil24

crudeoil24 2年前

Biodesix, Inc. is a United States-based company engaged in developing and commercializing blood-based diagnostic tests for oncology. The Company’s product Biodesix Lung Reflex integrates genomic and proteomic blood-based results to reveal both sides of lung cancer. Its GeneStrat test offers blood-based mutation results within 72 hours for patients with non-small cell lung cancer (NSCLC). Its VeriStrat testing provides blood-based predictive and prognostic proteomic information with (NSCLC) who test negative for estimated glomerular filtration rate (EGFR) mutations (EGFR wild-type) or whose EGFR mutation status is unknown.

Leg58

US based company is quietly trending up. IMHO.
GLTA

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約